Progress in diagnosis and treatment of steroid diabetes
Time：2022-07-21 Source：
参考文献(References)：
[1] Suh S,Park MK.Glucocorticoid-induced
diabetes mellitus:An important but overlooked problem[J].Endocrinol
Metab (Seoul),2017,32(2):180-189.DOI:10.3803/EnM.2017.32.2.180.
[2] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)(上)[J].中国实用内科杂志，2021,41(8):668-695.DOI:10.19538/j.nk2021080106.
[3]
Patel DA,Kristensen PL,Pedersen-Bjergaard U,et
al.Glucocorticoid-induced diabetes and risk factors during high-dose
therapy[J].Ugeskr Laeger,2018,180(18):V06170454.
[4]
Roberts A,James J,Dhatariya K.Management of hyperglycaemia and steroid
(glucocorticoid) therapy:a guideline from the Joint British Diabetes
Societies (JBDS) for Inpatient Care group[J].Diabet
Med,2018,35(8):10111017.DOI:10.1111/dme.13675.
[5] Zhao
Q,Zhou J,Pan Y,et al.The difference between steroid diabetes mellitus
and type 2 diabetes mellitus:a whole-body 18F-FDG PET/CT study[J].Acta
Diabetol,2020,57(11):1383-1393.DOI:10.1007/s00592-020-01566-w.
[6] 肖春燕，梁喜平，郭冰凌，等.非霍奇金淋巴瘤CHOP样方案化疗后继发类固醇糖尿病的相关危险因素分析[J].第三军医大学学报，2020,42(17):1743-1749.DOI:10.16016/j.1000-5404.202004073.
[7]
Sharma A,Maurya CK,Arha D,et al.Nod1-mediated lipolysis promotes
diacylglycerol accumulation and successive inflammation via PKCδ-IRAK
axis in adipocytes[J].Biochim Biophys Acta Mol Basis
Dis,2019,1865(1):136-146.DOI:10.1016/j.bbadis.2018.10.036.
[8]
Sugiyama T,Sugimoto T,Suzuki S,et al.Current smoking is an independent
risk factor for new-onset diabetes mellitus during highdose
glucocorticoid treatment[J].Int J Clin Pharmacol
Ther,2015,53(8):616-620.DOI:10.5414 /CP202136.
[9] Coll
S,Monfort N,Alechaga E,et al.Elimination profiles of prednisone and
prednisolone after different administration routes:Evaluation of the
reporting level and washout periods to ensure safe therapeutic
administrations[J].Drug Test
Anal,2021,13(3):571-582.DOI:10.1002/dta.2966.
[10] Yang
R,Yu Y.Glucocorticoids are double-edged sword in the treatment of
COVID-19 and cancers[J].Int J Biol
Sci,2021,17(6):1530-1537.DOI:10.7150/ijbs.58695.
[11] Liu
D,Ahmet A,Ward L,et al.A practical guide to the monitoring and
management of the complications of systemic corticosteroid
therapy[J].Allergy Asthma Clin
Immunol,2013,9(1):30.DOI:10.1186/1710-1492-9-30.
[12] 贾文娟，冯志美，张莹，等.糖皮质激素替代治疗对成人腺垂体功能减退症患者糖脂代谢的影响[J].药品评价，2021,18(1):32-34.DOI:10.19939/j.cnki.1672-2809.2021.01.09.
[13] 李倩娟，王聪蕊.动态血糖监测在2型糖尿病患者糖皮质激素治疗中的价值[J].中国卫生工程学，2019,18(3):452-454.
[14]
Magomedova L,Cummins CL.Glucocorticoids and metabolic
control[J].Handbook of Experimental
Pharmacology,2016,233:73-93.DOI:10.1007/164_2015_1.
[15]
Courty E,Besseiche A,Do TTH,et al.Adaptive β-cell neogenesis in the
adult mouse in response to glucocorticoid-induced insulin
resistance[J].Diabetes,2019,68(1):95-108.DOI:10.2337/db17-1314.
[16]
Finessi M,Bisi G,Deandreis D.Hyperglycemia and 18F-FDG PET/CT,issues
and problem solving:a literature review[J].Acta
Diabetol,2020,57(3):253-262.DOI:10.1007/s00592-019-01385-8.
[17]
Scaroni C,Zilio M,Foti M,et al.Glucose metabolism abnormalities in
cushing syndrome:from molecular basis to clinical management[J].Endocr
Rev,2017,38(3):189-219.DOI:10.1210/er.2016-1105.
[18]
Bódis K,Roden M.Energy metabolism of white adipose tissue and insulin
resistance in humans[J].Eur J Clin
Invest,2018,48(11):e13017.DOI:10.1111/eci.13017.
[19] 刘丽，宋囡，李军，等.毛蕊异黄酮葡萄糖苷与葛根素及其配伍对胰岛素抵抗脂肪细胞氧化应激的影响[J].辽宁中医杂志，2019,46(1):116-119.DOI:10.13192/j.issn.1000-1719.2019.01.039.
[20]
Beaupere C,Liboz A,Fève B,et al.Molecular mechanisms of
glucocorticoid-induced insulin resistance[J].Int J Mol
Sci,2021,22(2):623.DOI:10.3390/ijms22020623.
[21] Cui
A,Fan H,Zhang Y,et al.Dexamethasone-induced Krüppel-like factor 9
expression promotes hepatic gluconeogenesis and hyperglycemia[J].J Clin
Invest,2019,129(6):2266-2278.DOI:10.1172/JCI66062.
[22]
Kappe C,Fransson L,Wolbert P,et al.Glucocorticoids suppress GLP-1
secretion:possible contribution to their diabetogenic effects[J].Clin
Sci(Lond),2015,129(5):405-414.DOI:10.1042/CS20140719.
[23]
Akalestou E,Genser L,Rutter GA.Glucocorticoid metabolism in obesity and
following weight loss[J].Front Endocrinol
(Lausanne),2020,11:59.DOI:10.3389/fendo.2020.00059.
[24]
Rafacho A,Goncalves-Neto LM,Santos-Silva JC,et al.Pancreatic alpha-cell
dysfunction contributes to the disruption of glucose homeostasis and
compensatory insulin hypersecretion in glucocorticoid-treated
rats[J].PLoS One,2014,9(4):e93531.DOI:10.1371/journal.pone.0093531.
[25]
Esguerra JLS,Ofori JK,Nagao M,et al.Glucocorticoid induces human beta
cell dysfunction by involving riborepressor GAS5 LincRNA[J].Mol
Metab,2020,32:160-167.DOI:10.1016/j.molmet.2019.12.012.
[26] 邢昌赢，徐一力.类固醇糖尿病研究进展[J].肾脏病与透析肾移植杂志，2019,28(5):446-447.DOI:10.3969/j.issn.1006-298X.2019.05.009.
[27] 黄志伟，曾朝阳.类固醇糖尿病药物治疗研究进展[J].世界最新医学信息文摘，2019,19(66):116-117,120.DOI:10.19613/j.cnki.1671-3141.2019.66.056.
[28]
Seelig E,Meyer S,Timper K,et al.Metformin prevents metabolic side
effects during systemic glucocorticoid treatment[J].Eur J
Endocrinol,2017,176(6):349-358.DOI:10.1530/EJE-16-0653.
[29] 朱琳.西格列汀联合二甲双胍治疗2型糖尿病的疗效及对胰岛功能的影响[J].沈阳药科大学学报，2021,38(S1):40.
[30] 刘率男，刘泉，孙素娟，等.α葡萄糖苷酶抑制剂桑枝总生物碱的抗糖尿病作用研究[J].药学学报，2019,54(7):1225-1233.DOI:10.16438/j.0513-4870.2019-0212.
[31] 贾童林，陈刚，武俊伟，等.应用瞬感扫描式葡萄糖监测系统观察阿卡波糖对2型糖尿病患者血糖波动的影响[J].中国糖尿病杂志，2019,27(7):532-538.DOI:10.3969/j.issn.1006-6187.2019.07.011.
[32] 李敏，李芳，王玉珠，等.阿卡波糖生物等效性研究介绍[J].中国新药杂志，2020,29(23):2668-2671.DOI:10.3969/j.issn.1003-3734.2020.23.006.
[33]
Katsuyama H,Sako A,Adachi H,et al.Effects of 6-month sitagliptin
treatment on metabolic parameters in diabetic patients taking oral
glucocorticoids:a retrospective cohort study[J].J Clin Med
Res,2015,7(6):479-484.DOI:10.14740/jocmr2153w.
[34] Kalra S,Saboo B.Exenatide implant therapy in diabetes[J].J Pak Med Assoc,2018,68(10):1538-1540.
[35]
Elseady WS,Abd Ellatif RA,Estfanous RS,et al.New insight on the role of
liraglutide in alleviating dexamethasone-induced pancreatic
cytotoxicity via improving redox status,autophagy flux and PI3K/Akt/Nrf2
signaling[J].Canadian Journal of Physiology and
Pharmacology,2021,99(11):1217-1225.DOI:10.1139/cjpp-2021-0183.
[36]
Zhang J,Chen Y,Wang J,et al.The effect of liraglutide on insulin
allergy in a patient with glucocorticoid-induced diabetes and multiple
sclerosis[J].Nagoya J Med
Sci,2021,83(2):343-351.DOI:10.18999/nagjms.83.2.343.
[37]
Klarskov CK,Holm Schultz H,Persson F,et al.Study rationale and design
of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for
sTeroId diAbeTEs) - a randomized,controlled,multicenter trial of safety
and efficacy of treatment with empagliflozin compared with NPH-insulin
in patients with newly onset diabetes following initiation of
glucocorticoid treatment[J].BMC Endocrine
Disorders,2020,23(29):2668-2671.DOI:10.1186/s12902-020-00561-0.
[38]
American Diabetes Association.16.Diabetes advocacy:standards of medical
care in diabetes2019[J].Diabetes Care,2020,43(Suppl
1):S203S204.DOI:10.2337/dc20S016.
[39] Doyle-Delgado
K,Chamberlain JJ,Shubrook JH,et al.Pharmacologic approaches to glycemic
treatment of type 2 diabetes:Synopsis of the 2020 American Diabetes
Association's Standards of Medical Care in Diabetes Clinical
Guideline[J].Annals of Internal
Medicine,2020,8(1):2456-2470.DOI:10.7326/M20-2470.
[40]
Wallace MD,Metzger NL.Optimizing the treatment of steroid-induced
hyperglycemia[J].Ann
Pharmacother,2018,52(1):86-90.DOI:10.1177/1060028017728297.
